Chitosan nanocarrier |
Gemcitabine |
In vitro |
Oral adsorption |
[65] |
Chitosan/poly(ethylene glycol) |
Gemcitabine |
In vitro and in vivo |
Reduce the burden of frequent dosing and higher toxicity |
[66] |
Chitosan nanoparticle |
Herceptin (HER2)conjugated gemcitabine |
In vitro |
Eventual uptake and prolonged intracellular retention |
[67] |
O-carboxymethyl chitosan |
Curcumin |
In vitro |
Increase drug solubility |
[68] |
N-octyl-O-sulfate chitosan micelles |
Paclitaxel |
In vitro |
Solubilization of hydrophobic drugs |
[69] |
Glycol chitosan–5βcholanic acid (HGC) |
Camptothecin |
In vitro and in vivo |
Increase drug stability, solubility and retention |
[70] |
Hydroxyapatite chitosan nanocomposite |
Celecoxib |
In vitro and in vivo |
Sustained-release patterns |
[71] |